BioMarin Pharmaceutical Inc
BMRN58.640USD
+0.500+0.86%
交易中 （美东）报价延迟15分钟
11.24B总市值
21.46市盈率 TTM
关于 BioMarin Pharmaceutical Inc 公司
BioMarin Pharmaceutical Inc. (BioMarin) 是一家生物技术公司，致力于开发和商业化解决遗传病根源的疗法。BioMarin 的商业产品包括 Vimizim (elosulfase alpha)、Naglazyme (galsulfase)、Palynziq (pegvaliase-pqpz)、Brineura (cerliponase alfa)、Aldurazyme (laronidase)、Roctavian (valoctocogene roxaparvovec)、Kuvan (sapropterin dihydrochloride) 和 Voxzogo (vosoritide)。Vimizim 是一种酶替代疗法，用于治疗溶酶体贮积症 MPS IVA。Roctavian 是一种腺相关病毒 (AAV5) 载体基因疗法，旨在恢复重度血友病 A 患者的血浆因子 VIII 浓度。Voxzogo 是一种每日一次注射的 C 型利钠肽 (CNP) 类似物，用于治疗软骨发育不全。 Brineura 是一种重组人三肽基肽酶 1 (TPP1)，用于治疗患有 CLN2（一种巴顿病）的患者。
公司简介
公司代码BMRN
公司名称BioMarin Pharmaceutical Inc
上市日期Jul 23, 1999
CEOMr. Alexander Hardy
员工数量3040
证券类型Ordinary Share
年结日Jul 23
公司地址770 Lindaro Street
城市SAN RAFAEL
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94901
电话14155066700
网址https://www.biomarin.com/
公司代码BMRN
上市日期Jul 23, 1999
CEOMr. Alexander Hardy
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
62.99K
-53.04%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
46.81K
+61.08%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
Ms. Erin Burkhart
Ms. Erin Burkhart
Group Vice President, Chief Accounting Officer
Group Vice President, Chief Accounting Officer
14.18K
-16.41%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
8.83K
+305.05%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
8.83K
+305.05%
Ms. Elizabeth Mckey Anderson
Ms. Elizabeth Mckey Anderson
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
62.99K
-53.04%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
46.81K
+61.08%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Voxzogo
213.75M
29.10%
Vimizim
188.35M
25.64%
Naglazyme
114.29M
15.56%
Palynziq
93.27M
12.70%
Aldurazyme
48.98M
6.67%
Other
76.01M
10.35%
地区USD
名称
营收
占比
United States
241.69M
32.90%
Europe
229.58M
31.25%
Rest of the world
126.11M
17.17%
Latin America
88.28M
12.02%
ALDURAZYME net product revenues marked by Sanofi
48.98M
6.67%
业务
地区
业务USD
名称
营收
占比
Voxzogo
213.75M
29.10%
Vimizim
188.35M
25.64%
Naglazyme
114.29M
15.56%
Palynziq
93.27M
12.70%
Aldurazyme
48.98M
6.67%
Other
76.01M
10.35%
股东统计
更新时间: 5月18日 周日
更新时间: 5月18日 周日
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.87%
BlackRock Institutional Trust Company, N.A.
9.45%
PRIMECAP Management Company
9.27%
Dodge & Cox
7.80%
Viking Global Investors LP
5.63%
Other
57.99%
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.87%
BlackRock Institutional Trust Company, N.A.
9.45%
PRIMECAP Management Company
9.27%
Dodge & Cox
7.80%
Viking Global Investors LP
5.63%
Other
57.99%
股东类型
持股股东
占比
Investment Advisor
48.68%
Investment Advisor/Hedge Fund
35.44%
Hedge Fund
8.14%
Pension Fund
2.77%
Sovereign Wealth Fund
2.02%
Research Firm
1.30%
Bank and Trust
1.11%
Individual Investor
0.75%
Venture Capital
0.26%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
1323
192.81M
100.54%
-18.92M
2025Q1
1355
191.53M
99.87%
-20.72M
2024Q4
1336
190.53M
99.88%
-17.50M
2024Q3
1308
188.26M
98.81%
-22.17M
2024Q2
1293
192.58M
101.18%
-14.21M
2024Q1
1278
194.24M
102.38%
-11.23M
2023Q4
1294
193.16M
102.42%
-3.22M
2023Q3
1275
188.66M
100.18%
-4.68M
2023Q2
1283
185.80M
98.76%
-8.08M
2023Q1
1274
186.38M
99.36%
-9.64M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
18.92M
9.87%
-369.57K
-1.92%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
18.12M
9.45%
-16.94K
-0.09%
Mar 31, 2025
PRIMECAP Management Company
17.77M
9.27%
-415.89K
-2.29%
Mar 31, 2025
Dodge & Cox
14.96M
7.8%
+209.00K
+1.42%
Mar 31, 2025
Viking Global Investors LP
10.80M
5.63%
+289.51K
+2.75%
Mar 31, 2025
Capital Research Global Investors
9.15M
4.77%
-3.84M
-29.57%
Mar 31, 2025
State Street Global Advisors (US)
8.46M
4.41%
-649.18K
-7.12%
Mar 31, 2025
Columbia Threadneedle Investments (US)
3.62M
1.89%
-171.27K
-4.52%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
3.57M
1.86%
-49.67K
-1.37%
Dec 31, 2024
Elliott Management Corporation
3.50M
1.83%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco Biotechnology & Genome ETF
4.61%
Global X Genomics & Biotechnology ETF
3.49%
First Trust NYSE Arca Biotechnology Index Fund
3.04%
Goldman Sachs Future Health Care Equity ETF
2.69%
WealthTrust DBS Long Term Growth ETF
2.36%
SPDR S&P Biotech ETF
2.34%
Motley Fool Mid-Cap Growth ETF
1.87%
Virtus LifeSci Biotech Products ETF
1.85%
Alger Russell Innovation ETF
1.67%
VanEck Biotech ETF
1.53%
查看更多
Invesco Biotechnology & Genome ETF
占比4.61%
Global X Genomics & Biotechnology ETF
占比3.49%
First Trust NYSE Arca Biotechnology Index Fund
占比3.04%
Goldman Sachs Future Health Care Equity ETF
占比2.69%
WealthTrust DBS Long Term Growth ETF
占比2.36%
SPDR S&P Biotech ETF
占比2.34%
Motley Fool Mid-Cap Growth ETF
占比1.87%
Virtus LifeSci Biotech Products ETF
占比1.85%
Alger Russell Innovation ETF
占比1.67%
VanEck Biotech ETF
占比1.53%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
